Genitourinary Cancer in 2022 and Beyond

Expert perspectives and strategic insights on the latest therapeutic developments and translational research in genitourinary cancer treatment. Topics include clinical decision-making and the extent to which emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.

December 13 and 16, 2022
Daniel Petrylak, MD, Yale, Aptitude Health


Daniel Petrylak, MD

Yale University, New Haven, CT, USA

Faculty Members

Robert Dreicer, MD, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, USA

Karim Fizazi, MD, PhD
Institut Gustave Roussy, Villejuif, France

Thomas Powles, MBBS, MRCP, MD
Barts Cancer Centre, London, United Kingdom

Oliver Sartor, MD
Tulane University School of Medicine, New Orleans, LA, USA

Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Scott Tagawa, MD, FACP
Weill Cornell Medicine, New York, NY, USA

José Pablo Maroto Rey, MD, PhD
Instituto de Urología Serrate & Ribal, Barcelona, Spain

Joaquim Bellmunt, MD, PhD
Harvard Medical School, Boston, MA, USA

Manuela Schmidinger, MD
University of Vienna, Vienna, Austria

Sample Report

Start discovering the insights

View Report


  • Early-Stage Bladder Cancer (BCG-Resistant NMIBC; MIBC)
  • Current Paradigms and Future Directions in Metastatic Bladder Cancer
  • Evolving Paradigms for Metastatic RCC
  • Neo/Adjuvant Treatment of RCC
  • Current and Future Management of Non-clear Cell RCC
  • Advances in Imaging Technologies for Genitourinary Cancers
  • Treatment Paradigms for Advanced Prostate Cancer
  • Investigational Therapies for Metastatic CRPC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.